Citeline：2024年度临床试验完成情况白皮书：行业格局演变下的稳定根基探寻（英文版）

The findings from the past year, for each of the TAs, are emphasized within Table 1 and portray the TA ranking along with corresponding trial counts, comparatively. Oncology once again has far outstripped the other TAs and maintained its first-place rank for completed trial activity in 2024. As the distribution of trials tallied for the respective therapy areas mirrors that of 2023, commonality can also be seen with autoimmune/inflammation (A/I) in second rank, closely surpassing CNS, in the